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 Energy balance is considered a fundamental requirement of life forms from single cell 
organisms to higher mammals such as humans.  Unfortunately, our species has also discovered 
the detrimental metabolic responses to excess dietary intake: obesity and the accompanying 
pathologies collectively known as the metabolic syndrome.  Central to the metabolic syndrome is 
insulin resistance, defined as a relative failure of insulin to stimulate glucose transport in 
peripheral tissues such as skeletal muscle.  It is generally accepted that prolonged insulin 
resistance often results in the onset of type 2 diabetes, which is one of the most common diseases 
in the world.  Current treatment for type 2 diabetes generally begins with dimethylbiguanide, an 
insulin sensitizing drug also known as metformin.  In the last 10 years, scientific discovery has 
identified mitochondrial function as a key player in a variety of metabolic diseases, including 
insulin resistance and type 2 diabetes.  As such, a variety of investigations have been performed 
in an attempt to indentify mechanisms by which altered mitochondrial function or physiology 
may contribute to the pathogenesis of these diseases.  Recent evidence from our laboratory 
indicates that mitochondria derived oxidant (mROS) generation is a key player in the 
mitochondrial regulation of insulin sensitivity in vivo.  Additionally, recent evidence has 
demonstrated that acute metformin treatment in vitro decreases liver mROS, and that chronic 
 metformin treatment in vivo decreases skeletal muscle mROS concurrent with improvements in 
whole body glucose tolerance.  Together, this evidence indicates that metformin may alter 
peripheral insulin sensitivity by decreasing the elevated mROS associated with insulin resistance 
in the obese population.  Therefore, the purpose of the current study was to investigate the effects 
of a single oral dose of metformin on whole body glucose tolerance and mROS in red and white 
gastrocnemius of Zucker fa/fa rats, a genetically obese animal model.  A single oral dose of 
metformin resulted in improved whole body glucose tolerance compared to controls independent 
of alterations in serum insulin.  Cellular redox state was significantly more oxidized in animals 
treated with glucose or metformin alone compared to controls or animals which received both 
treatments.  Succinate and palmitoylcarnitine/malate induced mROS was not altered by glucose 
and/or metformin in red or white gastrocnemius.  Mitochondrial respiration with pyruvate/malate 
or palmitoylcarnitine/malate was unchanged in response to glucose and/or metformin treatment 
in red or white gastrocnemius.  Akt phosphorylation was significantly elevated in both red and 
white gastrocnemius in response to glucose or metformin alone, but no additive effect was 
observed when administered simultaneously, indicating that metformin may act as an insulin 
mimetic in vivo.  AMPK phosphorylation was not elevated in response to metformin treatment in 
either tissue, which suggests that metformin may act through AMPK-independent mechanisms in 
skeletal muscle in vivo.  The results of this study demonstrate that a single oral dose of 
metformin can improve whole body glucose tolerance independent of changes in mitochondrial 
respiration, mROS, or altered AMPK signaling in red and white gastrocnemius of Zucker fa/fa 
rats, but may be associated with altered cellular redox state.
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CHAPTER 1: REVIEW OF LITERATURE 
Introduction 
The prevalence of metabolic disease has been increasing to near pandemic rates in the 
past few decades.  A primary component of the metabolic syndrome is insulin resistance, which 
is associated with a myriad of associated pathologies, which include obesity and type II diabetes 
mellitus (T2DM).  Dimethylbiguanide, better known as metformin, has been used since the 
1930’s in the treatment of T2DM.  Although metformin has been extremely effective and 
perhaps the most commonly prescribed anti-diabetic drug in the last 50 years, the potential 
mechanisms of action for metformin are still largely unknown.  Recently obtained data in our 
laboratory has demonstrated a role for mitochondrial derived hydrogen peroxide (H2O2) in the 
pathogenesis of insulin resistance.  Our laboratory proposes that elevated mitochondrial 
superoxide (O2¯·) production and subsequent H2O2 emission (mH2O2) can induce a shift in the 
cellular redox environment to a more oxidized state, the result of which appears to be a major 
contributor to insulin resistance.  By decreasing mH2O2 in rat skeletal muscle mitochondria using 
pharmacological and transgenic manipulations, Anderson et al. (3) demonstrated that 
maintaining a reduced cellular redox environment can prevent high fat diet induced insulin 
resistance in high fat fed rats and mice.  Furthermore, our laboratory has recently demonstrated 
that the anti-diabetic action of metformin treatment is associated with decreased mitochondrial 
oxidant generation, specifically from Complex I of the electron transport system (ETS) (9).  It 
has been shown previously that metformin is a mild inhibitor of complex I of the ETS and 
metformin appears to decrease reverse electron flow through Complex I, which is a major 
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contributor of mH2O2 (39).  The purpose of this project was therefore to determine whether 
treatment with a single oral dose of metformin improves insulin sensitivity in the Zucker fa/fa 
rat, a genetic model of obesity and insulin resistance. 
 
Obesity and Diabetes 
Obesity has become an increasingly important health issue in recent years, particularly 
when considering the increasing prevalence of other metabolic syndrome related pathologies that 
accompany obesity.  Obesity results in an increased risk of developing non-insulin dependent 
diabetes mellitus (T2DM).  The link between obesity and T2DM has been thought to be largely 
due to the development and progression of skeletal muscle insulin resistance over the course of 
years (10).  Simply put, insulin resistance is defined as a relative failure of insulin to induce 
glucose transport in insulin sensitive tissues, principally skeletal muscle and adipose tissue.  
Skeletal muscle insulin resistance in vivo appears to be associated with reduced capacity for 
intramuscular lipid oxidation (reviewed by (32, 52)); however, the specific molecular 
mechanisms relevant to in vivo insulin resistance are incompletely understood.  Previous work 
has shown that obesity is associated with an increase in plasma and intramuscular lipid 
accumulation, both of which have been implicated as major contributors to the development and 
progression of skeletal muscle insulin resistance (41, 49). 
Insulin sensitivity is negatively correlated with plasma free fatty acids (FFA) in subjects 
with T2DM, and the extent to which insulin suppresses plasma FFA is thought to be a strong 
indicator of the severity of T2DM (41).  Further evidence to support the contribution of obesity 
to insulin resistance was provided by Amati et al. (2) who found that, regardless of age, insulin 
sensitivity was dependent on physical activity and obesity.  Additionally, Williams et al. (78) 
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found that clinically significant weight loss caused a large, yet incomplete, increase in insulin 
sensitivity in subjects with T2DM.  It is clear that based on the existing literature, obesity is a 
major contributor to insulin resistance and the pathogenesis of T2DM. 
Skeletal muscle of obese individuals displays a number of distinct features, perhaps most 
importantly a decrease in mitochondrial functional capacity, which appears to result from a 
decrease in both respiratory capacity (11, 51, 59) and mitochondrial content (59).  Obese 
individuals have also been shown to have lower fatty acid oxidation (FAO) at rest than lean 
individuals (45), and it has been suggested that this dysregulation in FAO is an essential factor 
contributing to insulin resistance in the obese state (40).  These observations have led to the 
hypothesis that insulin resistance may stem from a lower capacity to oxidize lipids in skeletal 
muscle as a result of acquired or inherited mitochondrial dysfunction which, in turn, leads to the 
accumulation of lipid metabolites that disrupt the insulin signaling pathway (47). 
Lipid Intermediates 
The obese phenotype provides an indication of decreased mitochondrial function, but 
recent evidence suggests that an acute high-fat diet or lipid infusion can induce insulin resistance 
independent of mitochondrial dysfunction by causing an elevation in lipid intermediates, 
specifically two products of long chain fatty acyl-CoA (LCACoA): diacylglycerol (DAG) and 
ceramide (22, 44).   LCACoA is the metabolically active form of triglyceride within the cell, and 
as such they are either sent to the mitochondria for β-oxidation or used as an intermediate for 
other lipid species such as DAG or ceramide.  DAG can be generated in a number of ways, but 
the most important source is via de novo synthesis by esterification of 2 LCACoAs to glycerol-3-
phosphate (74).  DAG has been implicated as a contributor to lipid-induced insulin resistance 
indirectly based on correlations found between DAG and PKCθ in Goto-Kakizaki and Zucker 
  4	  
rats (5).  Yu et al. (79) also found that lipid infusion caused a significant increase in DAG which 
was associated with PKCθ activity and increased IRS-1 Ser307 phosphorylation. 
Ceramide represents another intracellular lipid metabolite implicated in the development 
of insulin resistance.  Ceramide is a lipid metabolite generated in a similar fashion as DAG, and 
has been shown to directly activate PKC ζ, which suppresses Akt activity, and may contribute to 
insulin resistance (21).  An important difference between the effects of ceramide versus DAG on 
insulin resistance was found by Chavez et al (14), who found that ceramide contributed to 
saturated fat induced insulin resistance, but not DAG.  This does not nullify the potential role 
that DAG plays in lipid-induced insulin resistance, but is certainly noteworthy when considering 
the relative role of each.  The link between insulin resistance and obesity very well may be in the 
generation of DAG and ceramide (35); however, there is growing evidence that also suggests 
that decreases in β-oxidation may also play a large role in the etiology of insulin resistance 
independent of intramuscular lipid accumulation (56). 
Fatty Acid Oxidation 
Evidence supporting the theory that limitations in β-oxidation contribute to the 
development of insulin resistance has been primarily focused on the enzyme carnitine 
palmitoyltransferase 1 (CPT-1).  CPT-1 is an enzyme that is integral to β-oxidation as it 
increases fatty acid oxidation by increasing the uptake of long chain fatty acyl-CoA into the 
mitochondria.  CPT-1 plays an important role in the relationship between fatty acid oxidation, 
lipid intermediate generation and insulin resistance as evidenced by Dobbins et al. (19), who 
found that prolonged inhibition of CPT-1 or a diet high in saturated fat promoted diacylglycerol 
accumulation and insulin resistance in rats.  Further evidence of CPT-1 being integral to fatty 
acid oxidation was provided by Bruce et al. (12), who has shown that overexpressing CPT-1 in 
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skeletal muscle increases fatty acid oxidation, ameliorates lipid-induced insulin resistance in 
skeletal muscle, and does so without changes in mitochondrial capacity or function.  These 
findings suggest that the capacity for fatty acid oxidation is a contributor to insulin resistance in 
skeletal muscle in both the obese and high fat fed state, although the potential impact of 
overexpressing CPT1 on mitochondrial inner membrane integrity and total energy turnover was 
not considered or tested. 
Despite the popular theory of “mitochondrial dysfunction” as an underlying cause of 
insulin resistance (47), there is growing evidence indicating that a high-fat diet induces an initial 
increase in β-oxidation capacity and that loss of mitochondrial content only occurs after 
prolonged high fat intake (several months), well after the development of insulin resistance (31).  
Direct support of an increase in mitochondrial fatty acid oxidation resulting from a high fat diet 
was provided by Turner et al. (75), in which rats fed a high-fat diet for 5 or 20 weeks both 
showed an increase in palmitate oxidation compared to rats fed standard chow.   This increase in 
palmitate oxidation was accompanied by increased peroxisome proliferator-activated receptor γ 
co-activator 1α (PGC-1α) and uncoupling protein (UCP)-3 protein expression.  Hancock et al 
(28) found that rats fed a high-fat diet for 4 weeks displayed significant increases in PGC-1α 
protein although PGC-1α mRNA expression decreased.  The authors determined that the 
elevated FFA resulting from the high-fat diet caused a significant increase in peroxisome 
proliferator-activated receptor δ (PPARδ) mRNA expression, which increased PGC-1α protein 
expression.  Insulin resistance still occurred in the muscle as indicated by reduced insulin-
stimulated 2-DG transport assessed in vitro, clearly in the absence of any change in the 
mitochondria (28).  In addition, Garcia-Roves et al. (23) observed an increase in PPARδ binding 
to the muscle carnitine palmitoyltransferase 1 (mCPT-1) promoter in epitrochlearis muscle after 
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4 weeks of elevated FFA.  This was accompanied by a ~60% increase in palmitate oxidation, an 
increase in mCPT-1 mRNA, UCP-3 mRNA and mitochondrial TCA cycle enzyme activity.  It is 
interesting to note that mitochondrial biogenesis occurred without any observed change in 
PGC1-α gene expression.  Therefore, during a high-fat diet, it appears that fatty acid oxidation 
increases despite the development of insulin resistance. 
Insulin Signaling 
The insulin signaling pathway has long been implicated as the target of insulin resistance 
by obesity, high fat diet and lipid accumulation, and as such there are a number of targets in the 
insulin signaling pathway that are thought to be associated with insulin resistance.  Some of the 
components of the insulin signaling pathway implicated in insulin resistance include: Insulin 
Receptor (IR), Insulin Receptor Substrate-1 (IRS-1), Phosphatidylinositol-3 Kinase (PI-3K), 
Protein Kinase B (Akt), and Akt substrate of 160 kDa (AS-160).  In skeletal muscle, the insulin 
signaling cascade begins with insulin binding to the receptor on the cell membrane, which 
activates intrinsic tyrosine kinase activity of the IR which leads to auto-phosphorylation of the IR 
β-subunit and subsequent tyrosine phosphorylation of IRS-1.   Tyrosine phosphorylation of IRS-
1 recruits the p85 subunit of PI3K to the cell membrane (73).  From there, PI3K phosphorylates 
phosphatidylinositol 3,4-diphosphate (PIP2) to PIP3, and the increase in PIP3 recruits proteins 
containing pleckstrin homology (PH) domains, such as Akt and phosphinositide-dependent 
kinase 1  (PDK-1) to the cell membrane.  When Akt reaches the cell membrane, it is 
phosphorylated by PDK-1 on Thr308 (70, 71) and the mTOR-Rictor complex 2 (TORC2) on 
Ser473 (33, 64).  Once Akt is activated, AS160 is phosphorylated, which relieves the “brake” on 
GLUT4 translocation as evidenced by Sano et al. (63) who showed that when a mutant AS160 is 
deactivated, previous inhibition of GLUT4 translocation is alleviated.  Evidence that FFA 
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accumulation is associated insulin resistance was provided by Griffin et al. (27), who found that 
performing a 5-hour lipid infusion increased plasma FFA in Sprague Dawley rats, and the 
increased plasma FFA was associated with significant decreases in insulin-stimulated PI3K 
activity and IRS-1 tyrosine phosphorylation, as well as decreased glucose uptake.  Further 
supporting the obesity induced theory of insulin resistance, Standaert et al. (68) found that obese 
diabetic rhesus monkeys had significantly less IRS-1/PI3K activity as well as decreased insulin 
stimulated glucose uptake.  Based on the current literature, considerable evidence exists to 
suggest that FFA accumulation may be at least one mechanism by which high lipid intake 
induces insulin resistance. 
There is certainly evidence indicating that disruptions in the insulin signaling pathway 
caused by obesity and/or lipid accumulation contribute to insulin resistance; however, the extent 
that these disruptions contribute physiologically is still very controversial (22, 44).  The reason 
for the controversy is because although there may be disruptions in the insulin signaling 
pathway, the response may be non-linear, and may not even physiologically inhibit glucose 
uptake (44).  This thinking is based on a paper from Whitehead et al. (76) who showed that 
maximal insulin-stimulated glucose transport in adipocytes is achieved by activating only 10% 
and 20% of IRS-1 and Akt, respectively.  Although this may not hold true for skeletal muscle, 
especially when considering the relative quantity of glucose taken up by skeletal muscle 
compared to adipose tissue, the question still remains whether inhibition of the insulin signaling 
pathway by high fat diet or lipid intermediates inhibits glucose uptake under physiological 
conditions. 
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Electron leak and Superoxide generation 
The electron transport system is located on the mitochondrial inner membrane, which 
consists of four complexes, and is responsible for producing ATP with oxygen serving as the 
final electron acceptor to form H2O.  Although not pathological, during basal mitochondrial 
respiration a relatively small fraction of electrons (0.2-2%) leak from the ETS (13, 69).   Electron 
leak occurs at either complex I or III of the electron transport system as O2¯· and are converted to 
H2O2 by SOD in either the matrix or intermembrane space. H2O2 has an integral function in cell 
signaling through reversible cysteine oxidation (58).  Although H2O2 is emitted at low levels 
during basal mitochondrial respiration, H2O2 emission can increase dramatically under a variety 
of both physiological and pathophysiological conditions (4, 59).   When H2O2 emission is 
elevated, the redox state of the cell is altered due to the reversible oxidation of cysteine residues 
with specific proteins resulting in an overall shift in cellular redox environment to a more 
oxidized state (38). 
Regulation of Cellular Redox state 
Since the maintenance of the redox environment is clearly essential to the proper 
functioning of a cell, a number of therapies have been developed to attempt to prevent the 
production/accumulation of oxidants.  The drawback to antioxidant therapies in general is that 
most antioxidants are water soluble and, therefore, do not reach a sufficient concentration in the 
mitochondrial matrix to effectively scavenge O2¯·. 
Endogenously, cellular redox state is maintained primarily by the tri-peptide glutathione 
(GSH).  The oxidation of two glutathione molecules by glutathione peroxidase yields glutathione 
disulfide (GSSG); GSSG can be converted back into two glutathione molecules by the enzyme 
glutathione reductase.  GSH is found mainly (>98%) in the reduced form in the cytosol of 
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mammalian cells, with very little (<1%) found as GSSG (65).  The ratio of GSSG to GSH is 
commonly used as an index of the redox state of the cell, with a greater ratio indicative of 
oxidative stress.  Glutathione performs a variety of functions within a cell, from being the most 
abundant oxidant scavenger in the cytosol (50) to being an essential “on/off” switch for a number 
of cell signaling pathways through S-glutathionylation (17). 
Although the electron transport system is located on the inner membrane of the 
mitochondria, O2¯· is not released exclusively to the mitochondrial matrix.  Whereas O2¯· 
generated by complex I is released exclusively into the mitochondrial matrix, it has been recently 
shown that ~50% of O2¯· produced by complex III is released into the matrix and ~50% released 
into the intermembrane space (53, 67).  Recent work by Hu et al. (34) has shown the 
intermembrane space (IMS) is far more oxidizing than the mitochondrial matrix, and that the 
redox environment in the mitochondrial matrix and IMS are independently regulated by different 
isoforms of GSSG reductase.  This information combined with SOD isoforms being location 
specific (16) and O2¯· being highly membrane impermeable (43) ultimately demonstrates that 
separate compartmentalized redox environments are present within the mitochondria.  Therefore, 
it is clear that antioxidant therapies need to be specific in their localization in order to reach the 
mitochondrial matrix to scavenge electrons. 
Altered Insulin signaling by H2O2 
Oxidation of proteins can be particularly detrimental when the redox potential of the cell 
is already compromised, which occurs when there is an abundance of H2O2 present in the cell.  
H2O2 emission has been shown to increase in skeletal and cardiac muscle as a result of high fat 
feeding, and results in a disruption of the redox status of the cell (3).  A shift towards a more 
oxidative state in a cell causes disruption in numerous signaling pathways that rely on oxidation 
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as a key regulating mechanism.  The two main forms of reversible protein modification are 
glutathionylation and cysteine oxidation. 
Glutathionylation is a reaction that occurs when a cysteine residue on the tri-peptide 
glutathione (GSH) and a cysteine residue on a protein thiol are oxidized, and subsequently bind 
to form a mixed disulfide.  There are a number of different ways in which GSH can interact with 
a protein thiol, such as thiol/disulfide exchange and thiol oxidation, depending on the oxidation 
state of the thiol and GSH.  Protein S-glutathionylation occurs during basal conditions, 
suggesting a regulatory signaling function during physiological conditions (25).  The primary 
targets of glutathionylation are sulfhydryls and disulfides on proteins in oxidation sensitive 
regions, which are regions that are very basic (low pKa) or overly exposed due to their 3-D 
structure.  Beyond serving a regulatory role, it has been suggested that S-glutathionylation serves 
as a way of storing glutathione when it is sequestered as a result of binding to the protein thiol, as 
well as protecting protein thiols from non-reversible oxidation (48).  Glutaredoxin plays a role in 
both S-glutathionylation and in protein deglutathionylation. 
Cysteine is an amino acid that is particularly sensitive to oxidation, and is also a key 
component of numerous enzymatic reactions (58).  Active-site cysteine acts as a switch for a 
large number of cell signaling proteins, and is also quite abundant in the ion channels and 
receptors in the plasma membrane of cells.  Therefore, when the redox environment of the cell 
shifts to a more oxidized state, critical cysteine residues within specific key proteins can become 
glutathionylated or oxidized which can result in altered regulation of cell function. 
A growing line of inquiry linking insulin resistance to a disrupted redox state is focused 
on the downstream targets of TNFα, such as p38 mitogen-activated protein kinase (p38-MAPK) 
and the c-Jun NH2-terminal kinase (JNK).  JNK is activated by a number of stimuli, including 
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inflammatory cytokines such as tumor necrosis factor-α  (TNF-α).  The activation of JNK has 
been shown to positively correlate with serine307 phosphorylation of IRS-1 (30), which inhibits 
tyrosine phosphorylation of IRS-1 and in turn prevents downstream phosphorylation of 
phosphatidylinositol 3-kinase (PI3K), ultimately resulting in insulin resistance.  Further support 
implicating JNK as a negative regulator of IRS-1 tyrosine phosphorylation was provided by Lee 
et al. (46) which showed that a decrease in Ser307 phosphorylation and an increase in tyrosine 
phosphorylation in cells expressing a mutant IRS-1 lacking a JNK binding domain.  The 
decreased Ser307 phosphorylation was directly related to increased insulin-stimulated tyrosine 
phosphorylation, Akt phosphorylation and increased glucose uptake.  The prospect of JNK and 
upstream factors such as TNFα contributing to insulin resistance is a popular line of research 
currently. 
PTP1B is an interesting target because it has been shown to have an essential function in 
insulin signaling by dephosphorylating tyrosine residues on both the IR and IRS-1, which 
negatively regulates insulin signaling.  PTP1B is only active in the reduced (thiolate) form, but is 
highly susceptible to oxidation.  The reversible oxidized form (suphenic acid) can be converted 
back to the active form by amination to sulphenyl-amide and subsequent reduction (18).   During 
highly oxidizing conditions, PTP1B can be oxidized to sulphinic or sulphonic acid, which is 
irreversible.  Barrett et al. (8) found that s-glutathionylation prevented further oxidation from 
sulphenic acid, and that glutathionylation was an important regulator of PTP1B function.  
Although PTP1B may be an appealing target for studying insulin resistance, Zabolotny et al. (80) 
found that mice overexpressing PTP1B were shown to be insulin resistant, thus indicating that 
the dephosphorylation of the β-subunit of IR caused by the active form is a much larger 
contributor to insulin resistance than the concurrent dephosphorylation of IRS-1.  A possible 
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explanation for this may be that PTP1B was only shown to be a substrate for IRS-1 in vitro (26), 
so this response may not occur in vivo.  Therefore, available evidence to date indicates that a 
more oxidized redox environment may contribute to insulin resistance through MAPKs but 
probably not through regulation of PTP1B, and may be partially regulated by glutathionylation 
via regulatory pathways incorporating cysteine residues, but no specific pathways have been 
elucidated. 
Treatment of T2DM with Metformin 
Biguanides have been used as medicine since medieval Europe in the form of French 
lilac.  Two specific biguanides, phenformin and metformin, were finally isolated and synthesized 
in the 1930’s.  Phenformin is no longer in use due to the propensity for phenformin to induce 
lactic acidosis, but metformin has been in use in most of Europe since the 1950’s and in the 
United States since the 1980’s (6).  Dimethylbiguanide, better known as metformin, is one of the 
most widely prescribed pharmacological agents for T2DM.  Clinically, it is well established that 
metformin improves fasting glucose levels by decreasing hepatic glucose output and improving 
glucose tolerance by increasing insulin stimulated peripheral glucose uptake (reviewed in (7)).  
Although the clinical utility of metformin treatment is well established, the physiological 
mechanisms by which it acts are incompletely understood.  There are two predominantly 
interwoven theories regarding the physiological mechanism of metformin action:  altered 
electron flow through Complex I of the mitochondrial electron transport system (ETS) and 
activation of adenosine monophosphate activated protein kinase (AMPK).  Understanding the 
link between altered Complex I function and AMPK activation in the context of diabetes will be 
useful to elucidate the in vivo nature of metformin. 
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Cellular metabolism is very tightly controlled, with small alterations in energy state 
sometimes resulting in dramatic physiological changes.  An excellent example of the tight 
regulation of metabolism is the equilibrium state of the family of adenosine phosphates 
(ATP/ADP/AMP).  Since mitochondria are the primary source of ATP production in mammalian 
cells, mild alterations in the ETS of the mitochondria can result in global changes in cellular 
energy state (24).  Furthermore, since [ADP] and [AMP] are sustained at extremely low 
concentrations, very small absolute changes in either molecule can result in large relative 
changes.  Metformin has been shown to alter Complex I of the ETS in two ways: decreasing 
forward electron flow through Complex I which can result in decreased mitochondrial respiration 
and decreased [ATP], or decreasing reverse electron flow through Complex I which can result in 
decreased mitochondrial oxidant emission (9).  It has been shown recently in our lab that 
incubating rat red gastrocnemius muscle in different concentrations of metformin has 
concentration dependent effects on electron flow through Complex I (39).  Particularly, a ~100-
fold greater concentration of metformin was required to inhibit forward electron flow (evidenced 
by decreased mitochondrial O2 consumption) than was needed to inhibit reverse electron flow 
(evidenced by lower succinate supported H2O2 emission).  This data suggests that since reverse 
electron flow was altered at a much lower concentration of metformin, perhaps inhibition of 
reverse electron flow is a more relevant in vivo mechanism of action for metformin than the 
inhibition of forward electron flow. 
AMPK, a master cellular energy sensor (reviewed by (29)), can modulate metabolic 
pathways in response to altered energy states (i.e. increased [AMP]).  AMPK is present in a wide 
variety of cell types, including skeletal muscle and liver, and acts as a master metabolic switch in 
response to alterations in cellular energy state.  For example, AMPK activity is increased in 
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response to energy deficit (i.e. fasting conditions), which inhibits mTOR signaling by activating 
tuberous sclerosis factor (TSC) 1/2 and results in decreased protein synthesis (36).  The more 
general result of an increase in AMPK activity is a decrease in the activity of energy consuming 
pathways (i.e. protein synthesis) and an increase in the activity of energy producing pathways 
(i.e. β-oxidation and glycolysis). 
An increase in AMPK phosphorylation in response to 4 and 10 weeks of oral metformin 
treatment has been observed in type 2 diabetic human vastus lateralis, and was associated with 
improved skeletal muscle glucose transport in those subjects (54). Our lab has recently 
demonstrated that 4 weeks of oral metformin treatment induces improvements in whole body 
glucose tolerance in obese insulin resistant Zucker fa/fa rats (39).  Interestingly, Suwa et al, (72) 
have shown that AMPK phosphorylation can be significantly elevated in white gastrocnemius 
within 5 h after a single oral dose of metformin in healthy Wistar rats.  The apparent temporal 
sensitivity of AMPK activity to metformin treatment coupled with the powerful anti-diabetic 
action of metformin suggests that a perhaps a single dose of metformin may elicit similar anti-
diabetic effects as chronic treatment.  However, there are no published studies to date that have 
investigated the effect of a single dose of metformin on whole body glucose tolerance in either 
animal models or humans. Furthermore, it appears that the metabolic action of metformin can 
occur independently of AMPK in the myocardium, indicating that perhaps AMPK is not an 
essential contributor to the anti-diabetic action of metformin (61).

 	  
 
CHAPTER 2: PURPOSE AND HYPOTHESES 
Purpose 
The purpose of this study was to determine if a single oral dose of the anti-diabetic drug 
metformin can improve whole body glucose tolerance in the male fatty, insulin resistant Zucker 
rat model concomitant with altered mitochondrial oxidant production. 
Hypotheses: 
In Zucker fa/fa rats, a single oral dose of metformin will: 
1) Increase whole body glucose clearance in response to an oral glucose tolerance 
test (OGTT). 
2) Decrease mitochondrial H2O2 emission during succinate and palmitoyl-carnitine 
supported respiration. 
3) Not alter mitochondrial oxygen consumption during respiration supported by 
pyruvate/malate or palmitoyl-carnitine/malate. 
4) Improve insulin signaling. 
5) Not alter AMPK signaling. 
 	  
 
CHAPTER 3: METHODS 
Animals 
The male fatty (fa/fa) Zucker rats were obtained based on the severe obesity and insulin 
resistance that occurs in these animals between 8-12 weeks of age.  The fatty Zucker rat was 
chosen because recent work in this laboratory by Kane et al. (39) has demonstrated that 4 weeks 
of metformin treatment partially restores insulin sensitivity in Zucker fa/fa rats.  Therefore, the 
same animal model of insulin resistance was used to determine the effects of a single dose of 
metformin on whole body glucose clearance, skeletal muscle mitochondrial energetics, and 
skeletal muscle insulin signaling. 
Treatment Protocol 
This study was conducted in accordance with guidelines set forth by the East Carolina 
University Institutional Animal Care and Use Committee.  Twenty-four Zucker fa/fa rats were 
obtained and housed in a light (12 light: 12 dark) and temperature controlled (37°C) environment 
and allowed to eat and drink freely. 
Animals were fasted overnight (8-10 hours) and then given either an oral dose (320 
mg/kg body weight) of metformin (0.5 M dissolved in ddH2O) or a water gavage (2 ml/kg body 
weight) between 5-9 am.  The volume of water gavage given was equivalent to the volume of 
solution given to metformin treated animals.  Three hours after the “treatment” gavage, animals 
were given an OGTT (2 g/kg body wt.).  After the OGTT, animals were placed back into their 
respective cages and were allowed to eat and drink freely for >7 days.  Pharmacokinetic evidence 
indicates that metformin is completely removed from the circulation within 12 hours (62). 
After the week of washout, animals were again fasted overnight and then given either an 
oral dose of metformin or a water gavage in the same concentrations as the previous protocol.  
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However, 2 hours after the “treatment” gavage, each group (water or metformin) was divided 
into two subgroups (glucose or water) resulting in four groups: water/water, water/glucose, 
metformin/water, and metformin/glucose.  As such, two groups (water/glucose and 
metformin/glucose) received an oral glucose gavage (2 g/kg body weight) and the other two 
groups (water/water and metformin/water) received an equivalent volume of water.  One hour 
after the second gavage, the animals were given an intraperitoneal injection of ketamine/xylazine 
(50 mg/kg bodyweight) to induce deep anesthesia.  After anesthesia was confirmed using the toe 
pinch technique, the red and white gastrocnemius muscles were rapidly removed from the animal 
and either used for functional mitochondria measurements or flash frozen in liquid nitrogen for 
future analyses. 
Oral Glucose Tolerance Tests 
OGTTs were performed 3 hours after a single oral dose of metformin (320 mg/kg body 
weight) following an overnight fast using an oral glucose gavage (2 g/kg bodyweight).  
Approximately 1 ml of blood was collected from the lateral tail vein at baseline (minute 0), 15, 
30, 60, and 120 minutes after the glucose gavage was administered.  Blood glucose was 
measured using a whole blood glucometer (OneTouch Ultra).  For insulin, whole blood was 
collected in 1.5 ml Eppendorf tubes on ice, centrifuged at 10,000 rpm for 10 minutes, and the 
serum drawn off and frozen at -20°C.  Serum insulin was measured using a rat/mouse ELISA kit 
(Linco Research).  Homeostatic model assessment (HOMA) was calculated with the following 
formula: HOMA = fasting insulin (µU/ml) x fasting glucose (mM)/22.5. 
Preparation of permeabilized muscle fiber bundles 
This technique is partially adapted and has been described previously (3).  First, the red 
gastrocnemius muscle was dissected from the animal, and the muscle was separated into bundles 
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using a dissection microscope (Leica, Bannockburn, IL).  Fiber bundles were immersed in buffer 
X containing (mM): 60 K-MES, 35 KCl, 7.23 K2EGTA, 2.77 CaK2EGTA, 20 Imidazole, 0.5 
DTT, 20 Taurine, 5.7 ATP, 15 PCr, 6.56 MgCl2, - 6 H2O (pH 7.1, 290 mOsm), and separated 
using micro dissection instruments to maximize surface area.  The separated fiber bundles were 
then incubated in saponin (50 µg/ml) and buffer X for 30 minutes at 4°C to selectively 
permeabilize the plasma membrane.  After permeabilization, the de-energized fiber bundles 
(PmFBs) were washed for at least 15 minutes in Buffer Z containing: (mM) 110 K-MES, 35 
KCl, 1 EGTA, 5 K2HPO4, 3MgCl2 – 6 H2O, 5 mg/ml BSA, 0.05 pyruvate and 0.02 malate (pH 
7.4, 290 mOsm) on a rotator at 4° C and then stored at 4°C until analysis (<60 minutes). 
Mitochondrial O2 consumption 
 Oxygen consumption measurements were performed at 37°C in Buffer Z using the Oroboros 
O2K Oxygraph (Innsbruck, Austria).  Each chamber contained 2 ml of Buffer Z with 20 mM 
creatine monohydrate (to saturate endogenous creatine kinase), 5 mg/mL BSA, and 50 µM 
blebistatin (Bleb).  Bleb has been shown to be a myosin II inhibitor (1), and has been previously 
demonstrated to improve stability during O2 consumption experiments in permeabilized muscle 
fibers (Perry et al., unpublished observations).  After the fiber bundles were added, the chambers 
were sealed and upon signal stabilization, two different protocols were performed for each fiber 
type (red and white gastrocnemius) to analyze O2 kinetics. 
 Protocol 1: An ADP titration with pyruvate/malate as substrates was performed to determine 
whether metformin inhibits the sensitivity of the system to ADP (Km) or the maximal (Vmax) 
complex I supported respiration.  The protocol was performed as follows: i) 5 mM Malate and 2 
mM Pyruvate; ii) 25 µM ADP; iii) 100 µM ADP; iv) 250 µM ADP; v) 1 mM ADP; vi) 4 mM 
ADP.  During this protocol, reducing equivalents are derived almost exclusively from NADH 
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because the lack of succinate in the protocol prevents substantial flux through succinate 
dehydrogenase (SDH) which will thus limit the production of FADH2.  As a result, only forward 
electron flow through Complex I should occur.  Protocol 2: Maximal state 3 (ADP stimulated) 
respiration with Palmitoyl-carnitine/malate (PCM) was performed to determine if a single oral 
dose of metformin alters fatty acid supported respiration. The protocol was performed as follows: 
i) 25 µM palmitoyl carnitine + 1 mM malate (PCM4); ii) 25 µM ADP; iii) 100 µM ADP; iv) 250 
µM ADP; v) 1 mM ADP; vi) 4 mM ADP.  The first addition (PCM) initiates a state 4 basal, non-
phosphorylating respiration (PCM4). Reducing equivalents are derived from β-oxidation and the 
TCA cycle. ADP is then added to initiate state 3, phosphorylating respiration (PCM3). 
Methodological Considerations 
 Under experimental conditions, there are a number of limiting factors to respiration, such as 
[O2], substrate flux into the mitochondria, phosphorylation, and bulk electron flow.  In the 
current project, [O2] in the chamber was controlled for by maintaining [O2] within a given range 
(150-220 µM) at all times during the experiment.  This is done to avoid a situation where O2 
delivery is limited or in excess which could interfere with respiration independent of the ETS.  
Substrate flux into the mitochondria was controlled for by providing a maximal saturating 
concentration of each substrate or by performing a substrate titration during the experiment, 
effectively determining maximal substrate oxidation in a given protocol.  Limitations in ADP 
transport or phosphorylation occur at either the adenine nucleotide translocase or at the ATP 
synthase, respectively.  Although [O2] and substrate flux are controlled within the experimental 
design, the limitations regarding ADP transport and phosphorylation are analyzed as a whole 
primarily by calculating UCR.  A limitation in any of these systems will inhibit respiration 
relative to maximal uncoupled respiration.  Ultimately, assuming maximal substrate oxidation 
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and ideal [O2], bulk electron flow is the only limiting factor during maximal uncoupled 
respiration, and is recognized as the maximal rate of respiration in the given experimental 
protocols.  The protocols address each of the limitations in a step-wise fashion, providing a 
comprehensive analysis of mitochondrial respiratory function. 
 At the conclusion of each experiment, PmFBs were freeze-dried in a lyophilizer (Labconco) 
overnight.  After freeze-drying, the fibers were weighed and O2 consumption was expressed as 
pmol·sec-1·mg dry weight-1.    
Mitochondrial H2O2 Emission 
Mitochondrial H2O2 emission (mH2O2) was measured by continuously monitoring 
oxidation of Amplex Red using a Spex Fluoromax 3 (Jobin Yvon, Ltd.) spectrofluorometer.  
Chemically, this experiment is based on the oxidation of Amplex Red  (Invitrogen) by H2O2 in 
the presence of horseradish peroxidase (HRP) to form resorufin, which fluoresces at a 1:1 
stoichiometry with [H2O2], providing a direct measure of H2O2 emission.  The mH2O2 assay was 
set up by adding 300 µl of Amplex Red reagent with 1 µl HRP in a quartz cuvette.  Two 
protocols were employed for each fiber type (red and white gastrocnemius). 
Protocol 1: The first protocol performed consisted of the initial addition of 3 mM 
succinate followed by an ADP titration.  In order, the following substrates were added during the 
experiment: i) 3 mM Succinate; ii) 25 µM ADP; iii) 100 µM ADP; iv) 250 µM ADP; v) 500 µM 
ADP; vi) 1 mM ADP.  This protocol was used to induce a high rate of reverse electron flow 
through Complex I, and then to test the sensitivity of the mitochondria to [ADP] in a way similar 
to what was done while measuring O2 kinetics.  Although ADP was added for protocols 
measuring either O2 consumption or H2O2 emission, it is important to note that the addition of 
[ADP] will decrease membrane potential (ΔΨ), which will decrease mH2O2 concomitant with 
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greater O2 consumption.  Taken together, mitochondrial sensitivity to [ADP] under both of these 
conditions was performed to determine if metformin administration altered the dynamic 
relationship between adenine transport/phosphorylation and mH2O2. 
Protocol 2: The second protocol was done in two steps, first palmitoyl-carnitine and 
malate was added to measure fatty acid induced mH2O2.  The purpose of this part of the protocol 
was to measure fatty acid supported mH2O2 using an “activated” form of palmitate.  In order for 
fatty acids to enter the mitochondria for β-oxidation they must be converted to palmitoyl-
carnitine and then transported into the mitochondrial matrix via CPT 1/2.   Immediately 
afterwards, the fiber was removed, washed in fresh Buffer X and then added into a fresh cuvette.  
At this point, 3 mM succinate was added, followed by rotenone.  The purpose of the second step 
of the protocol was to see if metformin treatment inhibited complex I reverse electron flow to a 
similar degree as rotenone. 
At the conclusion of each mH2O2 experiment, the fiber bundles were washed in ddH2O, 
freeze-dried and weighed.  H2O2 emission data is expressed for each substrate condition as µmol 
H2O2/min/mg dry wt. 
Preparation of tissue for muscle protein 
A portion of red gastrocnemius collected at dissection was frozen in liquid N2 and 
powdered by pulverization.  To prepare samples for GSH analysis, 100mg of tissue was added to 
a test tube containing 1 ml of homogenization buffer consisting of (mM): 10 Tris, 1 EDTA, 1 
EGTA, 2 BaO, 2 Sodium Pyrophosphate (NaPPi), 5 sodium fluoride (NaF), and protease 
inhibitor cocktail at pH 7.2.  Tissue was then homogenized using a Polytron SC-250 set at 
25,000 rpm.  After homogenization, 1% Triton X-100 was added to the suspension, vortexed and 
put on ice for 5 minutes.  The tubes were then pelleted by centrifugation at 10,000 rpm for 10 
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minutes, supernatant decanted and the pellet stored at -80°C until muscle protein analysis is 
performed. 
 
Glutathione and Glutathione Disulfide analysis 
Total GSH (tGSH) and GSSG were measured using reagents and a calibration kit 
provided (Oxis Research) according to manufacturer’s instructions, with small modifications.  
For measurement of GSSG, samples were homogenized in the presence of 0.3 mM Methyl-2-
Vinylpyridinium triflate to scavenge all reduced thiols present in the sample.  From tGSH and 
GSSG, GSH/GSSG was calculated using the following formula: 
GSH/GSSG ratio = (tGSH – (2*GSSG))/ GSSG 
Analysis of protein signaling  
To extract proteins from tissues for the analysis of insulin signaling factors, frozen 
muscle was pulverized in liquid nitrogen with mortar and pestle, then placed in 10 volumes 
(~100 mg/1 ml buffer) of homogenization buffer (mM): 50 HEPES, 50 NaPPi, 100 NaF, 10 
EDTA, 10 NaO, 1% Triton X-100, and protease and phosphatase (1 and 2) inhibitor cocktails 
(Sigma, St. Louis, MO) on ice.  After centrifugation for 10 min at 10,000 rpm, supernatants were 
taken and protein content was determined using a BCA protein assay (Pierce, Rockford, IL).  An 
equal amount of protein was loaded into 12.5% Tris HCl gels, and gel electrophoresis was 
performed at 150 mV for ~1 hour.  The gels were then moved to a transfer apparatus in ice cold 
running buffer and proteins were transferred to a PVDF membrane for 2 hours at 100mV). 
Primary antibodies were then applied overnight in the following dilutions: total Akt (1:2000), 
Akt Ser473 (1:2000), total AMPK (1:1000), and AMPK Thr172 (1:1000).  Total Akt, total AMPK, 
and AMPK Thr172 antibodies were purchased from Cell Signaling (Beverly, MA).  Akt Ser473 
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was purchased from Santa Cruz Biotech (Santa Cruz, CA).  Following incubation with primary 
antibodies, blots were incubated with goat anti-rabbit horseradish peroxidase-conjugated 
secondary antibody purchased from Cell Signaling.  Horseradish peroxidase activity was 
assessed with Western Lightning ECL solution (Lumiglo and Peroxide, Cell Signaling, San 
Francisco, CA), and exposed to blue sensitive x-ray film. Exposure times were optimized for 
each particular experiment.  The resulting image was scanned and band densitometry was 
assessed with Gel Pro Analyzer software (Media Cybernetics, Silver Spring, MD).  Protein 
phosphorylation was calculated as the ratio of phosphorylated/total protein (i.e. pAkt/tAkt), 
normalized to the control fasted (water/water) animals and reported as % change from control. 
Statistical analysis 
Data is presented as mean + SEM.  Data was analyzed using two-tailed unpaired t-test for 
OGTT data and either one-way or two-way ANOVAs for all other measurements.  The 
significance level was set at p <0.05.
 	  
 
CHAPTER 4: RESULTS 
A single oral dose of Metformin improves Whole Body Glucose Tolerance. 
Glucose tolerance tests were performed on Zucker fa/fa rats 3 hours after an oral dose of 
metformin.  Fasting HOMA was significantly lower in metformin treated rats compared to 
control (Figure 1A - Control 3.96 + 0.44 vs. Metformin 2.75 + 0.28; p = 0.03).  This difference 
appears to be attributed to significantly lower fasting glucose in metformin treated animals 
(Figure 1B - Control - 121 + 4 vs. Metformin - 97 + 4; two-tailed t-test p < 0.0005) whereas no 
difference in fasting insulin (Figure 1C - Control  - 13.03 + 1.28 vs. Metformin - 11.36 + 0.97; 
two-tailed t-test p = 0.31) was observed.  Glucose AUC was significantly lower (35%) in 
metformin treated rats compared to the control group (Figure 2A - Control 33310 vs. Metformin 
21590; p < 0.0001) whereas insulin AUC was not significantly different between groups (Figure 
2B).  Taken together, these data provide evidence that a single dose of metformin improves 
whole body glucose tolerance, similar to the improvements in glucose tolerance observed with 
metformin treatment performed for several weeks (39). 
Mitochondrial O2 Consumption is not impaired by acute Metformin treatment 
Mitochondrial oxygen consumption was measured in both red and white gastrocnemius 
muscle of Zucker fa/fa rats three hours after an oral dose of metformin or water and then one 
hour after a glucose gavage or a second water gavage.  Mitochondrial oxygen consumption was 
measured during either pyruvate/malate (PM) or palmitoylcarnitine/malate (PCM) supported 
respiration utilizing an ADP titration to derive Km and Vmax.  As hypothesized, there were no 
statistically significant differences in Km or Vmax between any groups during PM or PCM 
supported respiration in red or white gastrocnemius.  Interestingly, although the theoretical Vmax 
for PM supported respiration was not different between water/water and metformin/water in red 
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gastrocnemius, the maximal ADP (4 mM) stimulated rate of respiration was significantly 
different between water/water and metformin/water (water/water – 708.3 + 95.70 vs. 
metformin/water – 1054.1 + 271.51; p < 0.05). 
Cellular Redox State is altered by a single oral dose of Metformin 
The ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) was measured 
and used as an index of cellular redox state.  White gastrocnemius GSH/GSSG was significantly 
decreased an hour after a glucose gavage in control animals, but in contrast, GSH/GSSG was 
significantly elevated in metformin treated animals in response to glucose (Figure 3A).  
However, contrary to expectations, water/water animals displayed a significantly greater 
GSH/GSSG ratio than metformin/water animals, suggesting that perhaps metformin has a 
deleterious effect on cellular redox state during fasting.  The altered GSH/GSSG ratios observed 
in the white gastrocnemius were not associated with significant differences in GSSG, which 
indicates that this response may not be exclusively due to alterations in mitochondrial oxidant 
production per se.  Furthermore, although significant differences were observed in the 
GSH/GSSG ratio in white gastrocnemius, no differences were observed in total GSH, GSSG, or 
GSH/GSSG in red gastrocnemius. 
Mitochondrial H2O2 emission is not decreased in skeletal muscle by a single oral dose of 
Metformin 
Mitochondrial H2O2 emission (mH2O2) was measured in both red and white gastrocnemius of 
Zucker fa/fa rats induced by either succinate or palmitoylcarnitine.  No significant differences 
between groups were observed in red gastrocnemius during succinate or PCM induced mH2O2 
(Figure 3B).  Additionally, no significant differences between groups were observed in white 
gastrocnemius during succinate or PCM induced mH2O2.  After the addition of succinate, an 
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ADP titration was performed to determine if metformin altered the reduction of mH2O2 in 
response to [ADP] in red gastrocnemius.  The percent (%) change was calculated by subtracting 
mH2O2 at a given [ADP] by the maximal succinate induced mH2O2 rate, then dividing by the 
maximal induced mH2O2 rate.  No differences were observed between groups in mH2O2 
sensitivity of red gastrocnemius to [ADP]. 
Akt but not AMPK phosphorylation is altered by acute Metformin treatment 
To determine the effects of a single dose of metformin on insulin signaling, 
phosphorylated (Ser473) and total Akt were measured by immunoblotting using equal amounts of 
protein in red and white gastrocnemius.  As expected, glucose treatment resulted in significantly 
elevated Akt Ser473 phosphorylation in red and white gastrocnemius compared to controls (181% 
and 280%, respectively), indicating activation of insulin signaling (Figure 4A).  Interestingly, 
metformin treatment resulted in elevated Akt Ser473 phosphorylation independent of glucose in 
both red and white gastrocnemius (323% and 176%, respectively) compared to fasted controls.  
Although both glucose and metformin increased Ser473 phosphorylation of Akt alone, treatment 
with both glucose and metformin did not have an additive effect. 
The current dogma with respect to metformin indicates that an increase in AMPK 
phosphorylation and/or activity is integral to its’ anti-diabetic effects (54, 81).  However, recent 
evidence indicates that activation of AMPK may not be required for particular metabolic effects 
of metformin (61, 72).  Therefore, to determine if a single dose of metformin causes increased 
AMPK phosphorylation, phosphorylated (Thr172) and total AMPK were measured by 
immunoblotting in red and white gastrocnemius.  No significant differences were observed 
between any groups in AMPK phosphorylation in response to glucose or metformin in red or 
white gastrocnemius (Figure 4B).  This data indicates that a single oral dose of metformin does 
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not cause an increase in AMPK phosphorylation, and furthermore that the anti-diabetic effects of 
metformin may not rely on AMPK, at least in skeletal muscle.
 	  
 
CHAPTER 5: DISCUSSION 
Summary of findings 
The results of the current study demonstrate a dramatic improvement in whole body glucose 
tolerance three hours after a single oral dose of metformin in Zucker fa/fa rats which is 
independent of changes in mH2O2 emitting potential or AMPK phosphorylation in red and white 
gastrocnemius.  Cellular redox state was differentially altered in response to glucose and/or 
metformin in white gastrocnemius, but no changes were observed in red gastrocnemius.  
Interestingly, the same trend seen in white gastrocnemius GSH/GSSG was observed in the 
mH2O2 emitting potential, although the latter was not statistically significant. The most 
significant finding of the current study is that a single dose of metformin dramatically improves 
whole body glucose tolerance in Zucker fa/fa rats, but does so independent of altered 
mitochondrial respiration, mitochondrial oxidant production, or AMPK phosphorylation.  Further 
investigation is needed to elucidate the mechanism responsible for the anti-diabetic action of 
metformin in skeletal muscle. 
Improved Glucose Tolerance after a single dose of Metformin 
Fasting glucose is primarily regulated by hepatic glucose output, and thus the 20% 
improvement in fasting glucose observed after a single oral dose of metformin in this study fits 
with previous data which has shown a dramatic reduction in hepatic glucose output in response 
to chronic metformin treatment in humans (37).  The improvement in whole body glucose 
tolerance observed in this study was not as great as the ~60% decrease in glucose AUC observed 
after 4 weeks of metformin treatment in Zucker fa/fa rats by Kane et al. (39).  However, it 
appears that a single dose of metformin resulted in a clinically relevant improvement in whole 
body glucose tolerance in both the fasted (20%) and fed (35%) states.  Furthermore, consistent 
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with previous findings from our lab, metformin treatment did not alter fasting serum insulin or 
total insulin area under the curve during an OGTT.  These data taken together are strong 
evidence to demonstrate the anti-diabetic action of metformin in skeletal muscle, which may 
require insulin (37), but can alter glucose tolerance independent of changes in insulin secretion 
as seen with chronic metformin treatment (39). 
Metformin acts independently of alterations in Mitochondrial Respiration to improve Whole 
Body Glucose Tolerance 
Previous research has suggested that the anti-diabetic effects of metformin may be due to 
inhibition of Complex I supported respiration (20, 55), however, many of these studies used 
metformin at concentrations many times higher than those which exist in vivo.  In the current 
study, a single dose of metformin did not alter maximal state 3 mitochondrial respiration in red 
or white gastrocnemius using pyruvate/malate or palmitoylcarnitine/malate as substrates.  This 
data suggests that skeletal muscle mitochondrial respiration is not altered after a single dose of 
metformin treatment, and furthermore that it is not required for the anti-diabetic effects of 
metformin treatment.  In further support of these findings, Kane et al. (39) recently demonstrated 
that the concentration of metformin needed to inhibit electron flow in the forward direction 
(respiration) was ~100 times greater than the concentration needed to inhibit reverse electron 
flow (oxidant generation).  Taken together, it appears fairly evident that although metformin is 
capable of inhibiting mitochondrial respiration in vitro at high concentrations, it is unlikely that 
metformin treatment alters skeletal muscle mitochondrial respiration in vivo. 
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A single dose of Metformin alters Cellular Redox state in a Skeletal Muscle Fiber Type specific 
manner 
Recent evidence has indicated that a potential mechanism for metformin to elicit anti-
diabetic effects is through the inhibition of mitochondrial oxidant production, particularly reverse 
electron flow through Complex I (9, 55).  In the current study, we tested whether a single dose of 
metformin altered mitochondrial H2O2 production induced by palmitoylcarnitine/malate or 
succinate in red and white gastrocnemius.  Contradictory to the hypotheses set forth, a single 
dose of metformin did not appear to significantly alter mitochondrial oxidant production in red 
gastrocnemius. 
Perhaps the most interesting finding of the current study was observed in white 
gastrocnemius cellular redox state.  As expected, water/glucose animals displayed a more 
oxidized GSH/GSSG ratio in white gastrocnemius compared to water/water, indicating that the 
cell redox environment became more oxidized in response to glucose.  However, when compared 
to the control fasted animals, metformin/water animals had a more oxidized cellular redox state 
(decreased GSH/GSSG) in white gastrocnemius.  However, when metformin and glucose 
treatments were given together (metformin/glucose group), the cellular redox environment was 
significantly more reduced (higher GSH/GSSG) compared to metformin/water animals, 
indicating a protective effect of metformin.  Although these results seem contradictory, there is 
evidence from previous studies to explain how/why this phenomenon may occur.  As mentioned 
previously, a key component of the metabolic action of metformin is thought to be through an 
increase in AMPK phosphorylation or activity, although in the current study, phosphorylation of 
AMPK did not appear to be elevated.  One observed result of metformin treatment (presumed to 
be AMPK dependent) is an increase in fatty acid oxidation and transport, which occurs through 
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phosphorylation of ACC, resulting in a decrease in malonyl-CoA levels (15).  Malonyl CoA is a 
competitive inhibitor of carnitine palmitoyl transferase 1 (CPT-1), and thus decreased levels of 
malonyl CoA result in greater fatty acid transport via CPT-1 (60).  Therefore, although perhaps 
not through an AMPK-dependent mechanism, if fatty acid transport and/or oxidation was 
elevated in the fasted state by metformin treatment, it could result in a more oxidized cellular 
redox environment due to elevated fatty acid supported mitochondrial oxidant generation (3).  
The dichotomy between red and white gastrocnemius may be explained by the different 
energetic properties of these two tissues, with red gastrocnemius possessing far greater 
mitochondrial density than white gastrocnemius.  Therefore, perhaps the same concentration of 
glucose (or metformin) affects these two tissues differently, which makes the response to 
metformin treatment difficult to compare between different fiber types. 
A single dose of Metformin can mimic Insulin signaling in the Fasted state 
The canonical insulin signaling cascade in skeletal muscle consists of a series of 
phosphorylation events beginning at the insulin receptor and culminating with GLUT4 
translocation to the plasma membrane.  At the epicenter of a variety of different signaling 
cascades, including insulin signaling, is the pro-survival kinase Akt.  In the current study, Akt 
phosphorylation was measured as an index of insulin signaling in red and white gastrocnemius.  
Consistent with previous findings, glucose treatment increased Akt phosphorylation, indicating 
an activation of insulin signaling.  Interestingly, metformin treatment alone significantly 
increased Akt phosphorylation in both red and white gastrocnemius, yet combined glucose and 
metformin did not have an additive effect on Akt phosphorylation on either tissue.  This data is 
provocative because previous findings indicate that insulin is necessary for metformin induced 
elevations of whole body glucose clearance (77).  However, based on the current findings, it 
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appears that perhaps insulin is not required for the anti-diabetic action of metformin in vivo, 
although this is based solely on protein signaling data since no direct measurements of skeletal 
muscle glucose transport were performed in the current study. 
Limitations 
Two types of limitations can be identified in this study: limitations based on the 
experimental models used and specific methodological limitations based on particular protocols.  
The primary limitations regarding experimental model and design are: lack of skeletal muscle 
specific glucose transport data and the use of a genetically predisposed obese animal as opposed 
to a naturally occurring type 2 diabetic animal.  The effects of a single dose of metformin on 
glucose tolerance in human or animal has only been assessed in one study to our knowledge (57).  
Perriello et al. (57) found that treating humans with a single dose of metformin resulted in 
dramatic reductions in hepatic glucose output with no alterations in peripheral glucose uptake.  
Ultimately, the current study provides inferential evidence that peripheral glucose transport was 
altered by a single dose of metformin based on the glucose AUC data, but when considering the 
previously reported contribution of hepatic glucose output in response to metformin treatment, 
specific skeletal muscle glucose transport data is needed.  The second major design limitation of 
the current study was the use of the Zucker fa/fa rat instead of a high fat fed rat.  The Zucker 
fa/fa rat is a leptin receptor deficient rat, meaning that leptin is released but cannot bind to 
receptors and act accordingly on feeding behavior, resulting in a hyperphagic animal that 
becomes insulin resistant between 10-12 weeks of age.  Previous research has demonstrated that 
metformin treatment improves leptin sensitivity in leptin-resistant high fat fed animals (42), and 
therefore the use of a leptin receptor deficient animal model lacks some strength in translating 
the animal data obtained in the current study to future humans studies.  The third and final 
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limitation related to design was the low group sizes as a result of unforeseen circumstances.  This 
resulted in group sizes of 3-4 in our functional mitochondria experiments, and yet another 
unfortunate event weakened the usefulness of stored frozen tissue, resulting in group sizes of 2-3 
for the western blot data presented in this study.  Therefore, all data except for the OGTT 
(glucose and insulin) and GSH/GSSG in this paper should be considered pilot data. 
Specific methodological limitations over the course of a study are commonplace as the 
development of new information and techniques become available.  The methodological 
limitations of the current study are primarily regarding the measurement of mitochondrial 
oxidant generation.  Specifically, based on the experimental conditions used, it is possible that 
the relative contribution of sites other than Complex I to altered mitochondrial oxidant 
production in response to metformin treatment may have been underestimated.  Previous 
research has indicated that Complex I was the primary target of metformin treatment (9).  
However, recent evidence from Seifert et al. (66) indicates that superoxide can be produced from 
the electron transferring flavoprotein as well as Complex III during fatty acid oxidation, and is 
therefore relevant to this study.  Furthermore, inclusion of exogenous CuZnSOD effectively 
doubles fatty acid induced H2O2 emission in isolated mitochondria (66).  This issue is paramount 
because our laboratory has used exogenous copper-zinc superoxide dismutase (CuZnSOD) in 
previous studies, the primary cytosolic superoxide scavenger in vivo, during the measurement of 
H2O2 emission, but exogenous CuZnSOD was not used in the current study because the 
contribution of Complex III to H2O2 emission was thought to be minimal (4).  This means that 
the relative contribution of alternate site oxidant generation may have been underestimated in the 
current study, and is a potential explanation for many of the discrepancies found between 
previous studies in our laboratory and the current study.  Therefore, although the results of the 
  34	  
current study did not fit some of the proposed hypotheses, methodological insight has been 
gained from this project and further investigation needs to be done to determine the topology of 
oxidant generation in response to glucose and/or metformin treatment.  
Future Directions 
 There are abundant opportunities in the future to study metformin, particularly because it 
is the most widely prescribed drug to type 2 diabetics while the mechanism of action is still 
largely unknown.  The current study has revealed novel descriptive responses to a single oral 
dose of metformin in the Zucker fa/fa rat, particularly with respect to whole body glucose 
tolerance and alterations in cellular redox state by metformin treatment. Potential future projects 
based on the insight gained from the current study should include direct measurements of hepatic 
glucose output and skeletal muscle glucose transport using radiolabeled tracers, and use either 
humans or high fat fed animal models instead of genetically obese animal models.  Investigating 
the role of AMPK as a biological target of metformin treatment in insulin sensitive tissues 
remains viable to study, as well as further exploring the insulin independent activation of insulin 
signaling proteins such as Akt, and how metformin treatment could affect protein synthesis 
through differential regulation of AMPK and Akt. 
 
Conclusions 
The current study tested the hypothesis that a single oral dose of metformin in genetically 
hyperphagic Zucker fa/fa rats would improve whole body glucose tolerance and be associated 
with decreased mitochondrial oxidant generation and improved cellular redox state.  Based on 
the results of the study, it can be concluded that a single dose of metformin results in 
improvements in whole body glucose tolerance that may be independent of changes in cellular 
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redox state or mitochondrial oxidant generation in red gastrocnemius, but related to altered 
cellular redox state in white gastrocnemius.  Metformin treatment in the fasted state may be 
detrimental to cellular redox state in white gastrocnemius, but should be tested further to 
determine if this is physiologically relevant.  Although threonine phosphorylation of AMPK was 
not increased in red or white gastrocnemius, serine phosphorylation of Akt was increased, 
indicating that metformin can mimic insulin to a certain extent in vivo and does not appear to 
rely on AMPK.  Cumulatively, the insight provided by the current study is descriptive and 
provides a solid foundation on which to pursue future studies regarding the acute metabolic 
alterations that occur in response to metformin treatment in vivo. 
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Figure 1: EFFECTS OF A SINGLE ORAL DOSE OF METFORMIN ON FASTING 
GLUCOSE AND INSULIN IN ZUCKER fa/fa RATS 
HOMA was calculated (A) (n=11/group) from fasting blood glucose (B) (n=12/group) and serum 
insulin (C) (n=11/group) which were measured after an overnight fast in Zucker fa/fa rats after 
either an oral dose of metformin (320 mg/kg body wt.) or an equivalent volume of water.  The 
results demonstrate the potential for metformin treatment (black bars) to improve HOMA (A - * 
P < 0.05) and decrease fasting glucose (B - *** P < 0.0001) compared to controls (white bars).  
Data is represented as the mean + SEM.
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Figure 2: EFFECTS OF A SINGLE DOSE OF METFORMIN ON WHOLE BODY GLUCOSE 
TOLERANCE IN OBESE ZUCKER fa/fa RATS 
Time course of blood glucose (A) during an OGTT (n=12/group).  Results indicate that a single 
dose of metformin decreases blood glucose at every time point beyond basal when assessed with 
2-way ANOVA and Bonferroni post-hoc test (** P < 0.01, *** P < 0.001).  Glucose (B) 
(n=12/group) and insulin (C) (n=11/group) total area under the curve (AUC) from an oral 
glucose tolerance test (2g/kg bodyweight) 3 hours after a single oral dose of metformin 
(320mg/kg bodyweight).  Results demonstrate that metformin treatment (black bars) improves 
whole body insulin sensitivity compared to controls (white bars) evidenced by decreased glucose 
AUC (*** P < 0.0001), but no significant difference in insulin AUC. Data is represented as the 
mean + SEM. 
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FIGURE 3: EFFECTS OF A SINGLE DOSE OF METFORMIN ON CELLULAR REDOX 
STATE AND MITOCHONDRIAL OXIDANT PRODUCTION IN RED AND WHITE 
GASTROCNEMIUS OF ZUCKER fa/fa RATS 
Cellular redox state (A) (n=6/group) and mitochondrial oxidant production (B) (n=3-4/group) 
were measured under four conditions (see Methods).  The first gavage was performed 3 hours 
prior to sacrifice and consisted of either metformin (320 mg/kg body wt.) or an equivalent 
volume of water, the second gavage was performed 1 hour before sacrifice and consisted of 
either glucose (2 g/kg body wt.) or an equivalent volume of water.  Therefore, four groups were 
studied (gavage 1/gavage 2): water/water (white bars), water/glucose (horizontal line bars), 
metformin/water (black bars), and metformin/glucose (vertical line bars).  The results indicate 
that red gastrocnemius cellular redox state is not altered by glucose or metformin treatment.  
However, in white gastrocnemius, metformin treatment alone resulted in a more oxidized cellular 
redox environment (* P < 0.05 vs. water/water, ✝ P < 0.05 vs. metformin/water), but when 
combined with glucose, metformin does not appear to alter cellular redox state.  Succinate 
supported mH2O2 was not significantly altered by metformin or glucose treatment in red or 
white gastrocnemius.  Together, this data indicates that there may be a fiber type specific 
amplitude of alterations in cellular redox state in response to metformin treatment.  Data are 
represented as the mean + SEM. (B is considered pilot data) 
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FIGURE 4: EFFECTS OF A SINGLE ORAL DOSE OF METFORMIN ON PROTEIN 
SIGNALING IN RED AND WHITE GASTROCNEMIUS OF ZUCKER fa/fa RATS 
To assess if a single dose of metformin altered protein signaling of Akt (A) and AMPK (B), 
phosphorylated and total content of these proteins was measured by immunoblotting (see 
Methods) and reported as phosphorylated/total (A and B – n=3/group).  Four groups were studied 
(gavage 1/gavage 2): water/water (white bars), water/glucose (horizontal line bars), 
metformin/water (black bars), and metformin/glucose (vertical line bars). The results indicate 
that glucose or metformin treatment alone are both capable of increasing Akt Ser473 
phosphorylation in both red ( * P < 0.05 vs. water/water, ** P < 0.01 vs. water/water) and white 
gastrocnemius (* P < 0.05 vs. water/water, *** P < 0.001 vs. water/water, ƒ P < 0.05 vs. 
water/glucose), but that glucose and metformin treatment together does not result in additive Akt 
phosphorylation in either tissue.  Conversely, glucose or metformin treatment alone did not result 
in an increase in AMPK phosphorylation, nor did combining the treatments.  This suggests that 
metformin can mimic insulin stimulation at the level of Akt, and that perhaps the metabolic 
action of metformin may occur independently of AMPK. (A and B are considered pilot data) 
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